The pan‐JAK inhibitor delgocitinib in a cream formulation demonstrates dose response in chronic hand eczema in a 16‐week randomized phase IIb trial *
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Dermatology"
DOI: 10.1111/bjd.21037
Abstract: Chronic hand eczema (CHE) is a burdensome disease, and new well‐documented, safe and efficacious treatments are warranted. In a recent CHE phase IIa trial, the pan‐Janus kinase (JAK) inhibitor delgocitinib in an ointment formulation was… read more here.
Keywords: chronic hand; hand eczema; jak inhibitor; inhibitor delgocitinib ... See more keywords